We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.64 | 18.23% | 4.15 | 3.50 | 4.80 | 173,867 | 16:35:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.80 | 10.36M |
From Apr 2021 to Apr 2024
TIDMPRM
RNS Number : 2011B
Proteome Sciences PLC
08 June 2021
8 June 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Grant of Options and PDMR/director shareholdings
Proteome Sciences announces the grant of options over new ordinary shares of 1p each in the Company ("Ordinary Shares") under the Company's share option schemes ("Options"). A total of 14,000,000 Options have today been issued to three directors of the Company.
Details of the Options granted to directors are outlined in the table below:
Hot Features
Premium
Name of Director Number of Options Total number
Granted of options now
held
Dr Mariola Soehngen 9,000,000 9,000,000
------------------ ----------------
Dr Ian Pike 2,500,000 2,500,000
------------------ ----------------
Mr Richard Dennis 2,500,000 2,500,000
------------------ ----------------
The Options are exercisable at the Ordinary Shares' nominal value of 1p per Option. For Dr Mariola Soehngen these Options will vest in three equal annual tranches on 15 September 2021, 2022 and 2023. For Dr Ian Pike and Mr Richard Dennis , the Options will vest in three tranches as to 1,000,000 on 15 September 2021 and 2022 and 500,000 on 15 September 2023. Each Option is exercisable into one Ordinary Share and once vested, can be exercised up until the 10th anniversary of today's date.
The Options granted today represent approximately 4.7 per cent of the Company's current issued share capital. In total 15,124,000 Options are now outstanding, representing approximately 5.1 per cent of the Company's current issued share capital.
Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.
For further information:
Proteome Sciences plc Tel: +44 (0)20 7043 Dr Mariola Soehngen, Chief Executive Officer 2116 Dr Ian Pike, Chief Scientific Officer Allenby Capital Limited (AIM Nominated Tel: +44 (0) 20 3328 Adviser & Broker) 5656 John Depasquale / Jeremy Porter
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
The below notification is made in accordance with the requirements of the UK Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Mariola Soehngen
----------------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status: Chief Executive Officer
----------------------------------------- ----------------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- ----------------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- ----------------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- ----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
0.01 9,000,000
----------
----------------------------------------- ----------------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
Exercisable
Price: at nominal
price of
1p per share 9,000,000
----------
----------------------------------------- ----------------------------------------
e) Date of the transaction: 8 June 2021
----------------------------------------- ----------------------------------------
f) Place of the transaction: N/A
----------------------------------------- ----------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Ian Pike
----------------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status: Chief Scientific Officer
----------------------------------------- ----------------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- ----------------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- ----------------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- ----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
0.01 2,500,000
----------
----------------------------------------- ----------------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
Exercisable
* Price: at nominal
price of
1p per share 2,500,000
----------
----------------------------------------- ----------------------------------------
e) Date of the transaction: 8 June 2021
----------------------------------------- ----------------------------------------
f) Place of the transaction: N/A
----------------------------------------- ----------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Richard Dennis
----------------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status: Chief Commercial Officer
----------------------------------------- ----------------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- ----------------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- ----------------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- ----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
Exercisable
at nominal
price of
1p per share 2,500,000
----------
----------------------------------------- ----------------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
Exercisable
Price: at nominal
price of
1p per share 2,500,000
----------
----------------------------------------- ----------------------------------------
e) Date of the transaction: 8 June 2021
----------------------------------------- ----------------------------------------
f) Place of the transaction: N/A
----------------------------------------- ----------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFVLFBFQLEBBX
(END) Dow Jones Newswires
June 08, 2021 07:54 ET (11:54 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
